Biotech bounced back in 2013, says report


Financial services firm EY says in its annual assessment of the global biotechnology sector that the industry is performing strongly, but needs to focus on using its R&D resources more efficiently to ‘unlock value’.

Revenues, R&D spending and companies’ ability to raise capital funding all increased in 2013 compared to 2012. But the report highlights a need for the industry to be smarter about how it spends that cash. Particularly, EY decries the high failure rate of expensive Phase III clinical trials. While this observation will not surprise anyone in the industry, the report draws on case studies from across the industry to suggest some strategies that might improve efficiency.

Chief among these is not skimping on earlier trials, and designing trials to be adaptive, so they can test multiple hypotheses and reach more definitive conclusions. Other recommendations reinforce trends that are already beginning to take hold within the pharmaceutical industry: using biomarker-based diagnostics to target products more effectively at populations where they will have greatest effect, and collaborating early and often, particularly on pre-competitive problems that affect the whole sector.


Related Content

Bounce denotes battery health

31 March 2015 Research

news image

Physical changes as battery discharges correlated with bounce

Sublime Leidenfrost

4 July 2013 Research

news image

Drop water on dry ice and a carbon dioxide layer will keep the water liquid and make it dance on (dry) ice

Most Read

Chemical linguistics

24 June 2015 Comments

news image

Chemistry is not language, explains Michael Gordin. But the metaphor is useful nonetheless

Z machine puts the squeeze on metallic deuterium

25 June 2015 Research

news image

Pressures similar to those at centre of the Earth forge metallic deuterium in step toward 80-year-old dream of creating metal...

Most Commented

New and expectant mothers: assessing the risk

24 June 2015 Webinars

news image

Get current, practical and relevant guidance on how to assess the risks and implement control measures for new and expectant ...

Collaboration, not competition

29 June 2015 Research

news image

Organic chemist E J Corey talks to Phillip Broadwith about awards, ambition and academic freedom